Myasthenia Gravis in Pregnancy

Akram Harazeen

University of Texas Medical Branch, Galveston, USA.

Vijaya Lakshmi Valaparla *

University of Texas Medical Branch, Galveston, USA.

Luz E Reiley

University of Texas Medical Branch, Galveston, USA.

Chilvana Patel

University of Texas Medical Branch, Galveston, USA.

*Author to whom correspondence should be addressed.


Abstract

This literature review provides a comprehensive insight into the management Myasthenia Gravis (MG) during pregnancy. It addresses the complexities of MG as an autoimmune neuromuscular disorder in the context of women during their childbearing period. The review synthesizes perspectives on the interaction between MG and pregnancy, highlighting increased risks and the necessity for tailored management strategies. It also delves into the pathophysiology of MG in pregnancy, including its impact on fertility, pregnancy outcomes, and lactation. The report underscores the importance of multidisciplinary care and individualized treatment plans, reflecting on medication adjustments and the role of thymectomy.

Keywords: Myasthenia gravis, autoantibodies, fertility, pregnancy, immunosuppressive medications, teratogenic, neonatal myasthenia, arthrogryposis, breastfeeding


How to Cite

Harazeen, Akram, Vijaya Lakshmi Valaparla, Luz E Reiley, and Chilvana Patel. 2024. “Myasthenia Gravis in Pregnancy”. Asian Journal of Research and Reports in Neurology 7 (1):111-29. https://journalajorrin.com/index.php/AJORRIN/article/view/109.